Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Extension Study in Subjects From Prior Venetoclax Trials
jRCT2051220047Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc. Primary endpoint: Adverse Events. Started Jul 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051220047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220047.